ATE481134T1 - COMPOSITIONS AND USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PATHOGENIC INFECTIONS - Google Patents
COMPOSITIONS AND USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PATHOGENIC INFECTIONSInfo
- Publication number
- ATE481134T1 ATE481134T1 AT05705915T AT05705915T ATE481134T1 AT E481134 T1 ATE481134 T1 AT E481134T1 AT 05705915 T AT05705915 T AT 05705915T AT 05705915 T AT05705915 T AT 05705915T AT E481134 T1 ATE481134 T1 AT E481134T1
- Authority
- AT
- Austria
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- compositions
- treatment
- pathogenic infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Compositions and methods are provided for using tyrosine kinase inhibitors to treat pathogenic infection. In particular, methods for using Abl-family tyrosine kinase inhibitors to treat pathogenic infection are provided. Infections to be treated according to the present invention include, particularly, those caused by microbial pathogens such as bacteria and viruses.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53796004P | 2004-01-21 | 2004-01-21 | |
US55368104P | 2004-03-16 | 2004-03-16 | |
US61420304P | 2004-09-29 | 2004-09-29 | |
PCT/US2005/001710 WO2005072826A2 (en) | 2004-01-21 | 2005-01-20 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE481134T1 true ATE481134T1 (en) | 2010-10-15 |
Family
ID=34831196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05705915T ATE481134T1 (en) | 2004-01-21 | 2005-01-20 | COMPOSITIONS AND USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PATHOGENIC INFECTIONS |
Country Status (8)
Country | Link |
---|---|
US (1) | US8765777B2 (en) |
EP (3) | EP1725295B1 (en) |
JP (2) | JP5520433B2 (en) |
AT (1) | ATE481134T1 (en) |
AU (1) | AU2005209231B8 (en) |
CA (1) | CA2554201C (en) |
DE (1) | DE602005023587D1 (en) |
WO (1) | WO2005072826A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1725295B1 (en) | 2004-01-21 | 2010-09-15 | Emory University | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection |
TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
TWI393565B (en) * | 2004-06-04 | 2013-04-21 | Bioniche Life Sciences Inc | Use of imatinib mesylate to treat liver disorders and viral infections |
WO2006017353A2 (en) * | 2004-07-13 | 2006-02-16 | GOVERNMENT OF THE UNITED STATES, as represented byTHE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Treatment of viral infections |
TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
WO2007002441A1 (en) * | 2005-06-24 | 2007-01-04 | Emory University | Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection |
EP1862802B1 (en) * | 2006-06-01 | 2008-12-10 | Cellzome Ag | Methods for the identification of ZAP-70 interacting molecules and for the purification of ZAP-70 |
US8268809B2 (en) | 2006-09-05 | 2012-09-18 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
WO2008151183A1 (en) | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
US8367686B2 (en) | 2007-06-07 | 2013-02-05 | Intra-Cellular Therapies, Inc. | Heterocycle compounds and uses thereof |
WO2008153974A1 (en) | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Novel heterocycle compounds and uses thereof |
JP6166534B2 (en) | 2009-08-05 | 2017-07-19 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2012118599A1 (en) * | 2011-02-28 | 2012-09-07 | Emory University | C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication |
ES2650630T3 (en) | 2011-10-03 | 2018-01-19 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for cancer treatment |
CA2873878A1 (en) | 2012-05-22 | 2013-11-28 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
US9487500B2 (en) | 2012-10-04 | 2016-11-08 | Inhibikase Therapeutics, Inc. | Compounds and compositions thereof |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
EP2769722A1 (en) * | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
MX2015011514A (en) | 2013-03-15 | 2016-08-11 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof. |
TWI647220B (en) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | Heteroaryl compound and its use |
KR102350704B1 (en) | 2013-03-15 | 2022-01-13 | 셀젠 카르 엘엘씨 | Heteroaryl compounds and uses thereof |
EP2905024A1 (en) * | 2014-02-07 | 2015-08-12 | Institut Quimic De Sarriá Cets, Fundació Privada | Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae |
EP3129377A4 (en) * | 2014-04-11 | 2017-12-20 | The University of North Carolina at Chapel Hill | Mertk-specific pyrimidine compounds |
WO2017049036A1 (en) * | 2015-09-16 | 2017-03-23 | Emory University | Use of kinase inhibitors to manage tuberculosis and other infectious diseases |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
US20200360477A1 (en) | 2019-05-16 | 2020-11-19 | Aerovate Therapeutics, Inc. | Inhalable formulations for kinase inhibition |
US11464776B2 (en) | 2019-05-16 | 2022-10-11 | Aerovate Therapeutics, Inc. | Inhalable imatinib formulations, manufacture, and uses thereof |
KR20220054808A (en) * | 2019-09-04 | 2022-05-03 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Functional and phenotypic regeneration of connective tissue through Npas2 inhibition |
CN111925368B (en) * | 2020-07-04 | 2021-11-05 | 中国医学科学院医药生物技术研究所 | Pyrimidone derivatives, preparation method thereof and application thereof in resisting mycobacterium tuberculosis infection |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU11248A1 (en) | 1927-03-29 | 1929-09-30 | В.С. Григорьев | Anthracene cleaning method |
US3439089A (en) | 1968-03-27 | 1969-04-15 | Merck & Co Inc | Medicated hard candy |
US4439089A (en) | 1978-10-12 | 1984-03-27 | Dresser Industries, Inc. | Boom arm with rock deflection feature |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (en) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
GEP20012444B (en) | 1994-11-14 | 2001-05-25 | Warner Lambert Company Us | 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation |
CN1311678A (en) | 1998-04-30 | 2001-09-05 | 巴斯福股份公司 | Substituted tricyclic pyrazole derivatives with protein kinase activity |
CN101481359A (en) | 1999-04-15 | 2009-07-15 | 布里斯托尔-迈尔斯斯奎布公司 | Cyclic protein tyrosine kinase inhibitors |
ATE392215T1 (en) * | 1999-12-22 | 2008-05-15 | Scripps Research Inst | MODULATORS AND INHIBITORS OF ANGIOGENESIS AND VASCULAR PERMEABILITY |
JP2004520007A (en) * | 2000-08-01 | 2004-07-08 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Gene expression profile of KSHV infection and method of treating KSHV infection |
US7022711B2 (en) * | 2000-08-04 | 2006-04-04 | Warner-Lambert Company | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
PT1330452E (en) | 2000-09-20 | 2009-01-22 | Ortho Mcneil Pharm Inc | Pyrazine derivatives as modulators of tyrosine kinases |
EP1201765A3 (en) * | 2000-10-16 | 2003-08-27 | Axxima Pharmaceuticals Aktiengesellschaft | Cellular kinases involved in cytomegalovirus infection and their inhibition |
US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
MXPA03005777A (en) | 2000-12-22 | 2005-02-14 | Johnson & Johnson | Substituted triazole diamine derivatives as kinase inhibitors. |
US20040241226A1 (en) * | 2001-09-20 | 2004-12-02 | Alain Moussy | Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
GB0125659D0 (en) | 2001-10-25 | 2001-12-19 | Ssl Int Plc | Spermicides |
FR2844452A1 (en) | 2002-09-18 | 2004-03-19 | Inst Gustave Roussy Igr | Modulating dendritic cell activity, e.g. for treatment of viral infections, NK-sensitive tumors or autoimmune diseases, using inhibitors or specific tyrosine kinases, e.g. c-abl, bcr/abl and c-kit |
US7384907B2 (en) | 2002-12-13 | 2008-06-10 | Duke University | Method of treating infection with ABl tyrosine kinase inhibitors |
WO2005003325A2 (en) * | 2003-03-11 | 2005-01-13 | Dana Farber Cancer Institute | Inhibition of viral pathogenesis |
EP1725295B1 (en) | 2004-01-21 | 2010-09-15 | Emory University | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection |
WO2005105097A2 (en) * | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
TWI393565B (en) * | 2004-06-04 | 2013-04-21 | Bioniche Life Sciences Inc | Use of imatinib mesylate to treat liver disorders and viral infections |
WO2007002441A1 (en) | 2005-06-24 | 2007-01-04 | Emory University | Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection |
US8268809B2 (en) | 2006-09-05 | 2012-09-18 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
-
2005
- 2005-01-20 EP EP05705915A patent/EP1725295B1/en not_active Not-in-force
- 2005-01-20 JP JP2006551238A patent/JP5520433B2/en active Active
- 2005-01-20 WO PCT/US2005/001710 patent/WO2005072826A2/en active Application Filing
- 2005-01-20 DE DE602005023587T patent/DE602005023587D1/en active Active
- 2005-01-20 EP EP10006352A patent/EP2260849A1/en not_active Ceased
- 2005-01-20 EP EP10006351.0A patent/EP2233174B1/en not_active Not-in-force
- 2005-01-20 AU AU2005209231A patent/AU2005209231B8/en not_active Ceased
- 2005-01-20 CA CA2554201A patent/CA2554201C/en not_active Expired - Fee Related
- 2005-01-20 AT AT05705915T patent/ATE481134T1/en not_active IP Right Cessation
-
2010
- 2010-06-24 JP JP2010144115A patent/JP2010202674A/en active Pending
- 2010-12-16 US US12/969,659 patent/US8765777B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5520433B2 (en) | 2014-06-11 |
EP2233174B1 (en) | 2016-07-20 |
DE602005023587D1 (en) | 2010-10-28 |
EP1725295B1 (en) | 2010-09-15 |
US20110281867A1 (en) | 2011-11-17 |
AU2005209231A1 (en) | 2005-08-11 |
US8765777B2 (en) | 2014-07-01 |
JP2007518810A (en) | 2007-07-12 |
CA2554201A1 (en) | 2005-08-11 |
EP2233174A1 (en) | 2010-09-29 |
JP2010202674A (en) | 2010-09-16 |
AU2005209231B8 (en) | 2011-07-28 |
WO2005072826A3 (en) | 2006-04-20 |
EP2260849A1 (en) | 2010-12-15 |
WO2005072826A2 (en) | 2005-08-11 |
AU2005209231B2 (en) | 2011-03-17 |
CA2554201C (en) | 2015-04-14 |
EP1725295A2 (en) | 2006-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE481134T1 (en) | COMPOSITIONS AND USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PATHOGENIC INFECTIONS | |
MA33806B1 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
DE602005012276D1 (en) | USE OF PROBIOTIC BACTERIA FOR THE PREPARATION OF TOPICAL COMPOSITIONS FOR THE PROTECTION OF THE SKIN | |
DE60309701D1 (en) | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLENE DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND / OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
ATE489957T1 (en) | AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
HK1137366A1 (en) | Pharmaceutical compositions comprising activin-actriia antagonists and use thereof in preventing or treating multiple myeloma | |
DE602008004317D1 (en) | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | |
ATE551343T1 (en) | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | |
ATE492542T1 (en) | PREPARATION AND USE OF BIPHENYL-4-YL CARBONYLAMINOSIC ACID DERIVATIVES FOR THE TREATMENT OF OBESITAS | |
ATE506951T1 (en) | TERTIARY CARBINAMINES ACTIVE AS INHIBITORS OF BETA-SECRETASE WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
EA200702493A1 (en) | CONNECTIONS AND METHODS OF TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | |
ATE439863T1 (en) | OPHTHALMIC PARASYMPATHIC STIMULANT AND ANTI-INFLAMMATORY COMPOSITIONS FOR USE IN THE TREATMENT OF PRESBYOPIA | |
DE602004014117D1 (en) | THIAZOLE FOR USE AS INHIBITORS OF PROTEIN KINASES | |
NO20082862L (en) | Novel alkylphospholipid derivatives with reduced cytotoxicity and use thereof | |
DE602008006257D1 (en) | CYCLOPROPYL-CONDENSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | |
EA201100874A1 (en) | COMPOUNDS FOR CANCER TREATMENT | |
DE60307749D1 (en) | Use of flavonoid derivatives for the treatment of atopic eczema | |
EA200702583A1 (en) | USE OF PHYLICEMIC BARBONS FOR TREATING SEEDS | |
ATE555108T1 (en) | POLYAMIDES FOR THE TREATMENT OF HUMAN PAPILLOMA VIRUS | |
ATE445644T1 (en) | APPLICATION OF MOLECULES AND METHODS TO TREAT MCP-1/CCR2 ASSOCIATED DISEASES | |
DE602005018366D1 (en) | FOR THE TREATMENT OF 4-PIPERAZINYLPYRIMIDIN COMPOUNDS SUITABLE FOR MODULATION OF THE DOPAMIN D3 RECEPTOR | |
DE602004022689D1 (en) | USE OF PROBIOTIC BACTERIA FOR THE TREATMENT OF INFECTIONS | |
ATE473277T1 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | |
WO2010052575A3 (en) | Ngna compositions and methods of use | |
ATE498398T1 (en) | CYCLOALKYL HETEROCYCLES FOR THE TREATMENT OF HEPATITIS C VIRUS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |